1. Home
  2. SPHL vs INDP Comparison

SPHL vs INDP Comparison

Compare SPHL & INDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SPHL
  • INDP
  • Stock Information
  • Founded
  • SPHL 2002
  • INDP 2000
  • Country
  • SPHL Singapore
  • INDP United States
  • Employees
  • SPHL N/A
  • INDP N/A
  • Industry
  • SPHL Homebuilding
  • INDP Biotechnology: Pharmaceutical Preparations
  • Sector
  • SPHL Consumer Discretionary
  • INDP Health Care
  • Exchange
  • SPHL Nasdaq
  • INDP Nasdaq
  • Market Cap
  • SPHL 6.1M
  • INDP 5.0M
  • IPO Year
  • SPHL 2024
  • INDP N/A
  • Fundamental
  • Price
  • SPHL $0.53
  • INDP $11.12
  • Analyst Decision
  • SPHL
  • INDP Strong Buy
  • Analyst Count
  • SPHL 0
  • INDP 2
  • Target Price
  • SPHL N/A
  • INDP $8.50
  • AVG Volume (30 Days)
  • SPHL 206.8K
  • INDP 689.8K
  • Earning Date
  • SPHL 02-21-2025
  • INDP 08-11-2025
  • Dividend Yield
  • SPHL N/A
  • INDP N/A
  • EPS Growth
  • SPHL N/A
  • INDP N/A
  • EPS
  • SPHL N/A
  • INDP N/A
  • Revenue
  • SPHL $6,456,601.00
  • INDP N/A
  • Revenue This Year
  • SPHL N/A
  • INDP N/A
  • Revenue Next Year
  • SPHL N/A
  • INDP N/A
  • P/E Ratio
  • SPHL N/A
  • INDP N/A
  • Revenue Growth
  • SPHL N/A
  • INDP N/A
  • 52 Week Low
  • SPHL $0.35
  • INDP $7.56
  • 52 Week High
  • SPHL $7.80
  • INDP $67.48
  • Technical
  • Relative Strength Index (RSI)
  • SPHL N/A
  • INDP 98.13
  • Support Level
  • SPHL N/A
  • INDP $0.31
  • Resistance Level
  • SPHL N/A
  • INDP $0.71
  • Average True Range (ATR)
  • SPHL 0.00
  • INDP 0.07
  • MACD
  • SPHL 0.00
  • INDP 0.77
  • Stochastic Oscillator
  • SPHL 0.00
  • INDP 99.09

About SPHL Springview Holdings Ltd Class A Ordinary Shares

Springview Holdings Ltd is a company that conducts its operations through its indirect wholly-owned subsidiary which designs and constructs residential and commercial buildings in Singapore. It also provides four main types of works which includes new construction, reconstruction, Additions and Alterations (A&A), and other general contracting services such as renovation and design consultation. The company operates and manages its business as a single segment - in the development of construction projects. It derives maximum revenue from its Residential Customers.

About INDP Indaptus Therapeutics Inc.

Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma models.

Share on Social Networks: